Advertisement

International Orthopaedics

, Volume 35, Issue 3, pp 341–348 | Cite as

Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)

  • Tomáš TrčEmail author
  • Jana Bohmová
Original Paper

Abstract

This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged ≥40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient’s and investigator’s global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire). Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech®) and significant differences were observed. Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech® (p < 0.05): WOMAC index decrease ≤ 15 points at the last visit (day 90) for Colatech® in 16 patients (34.04%) (p < 0.05) and for glucosamine in six patients (13.04%); total score index for painful joints: Colatech® 1.6 (p < 0.05) and glucosamine 1.8; total score index for swollen joints: Colatech® 0.5 (p < 0.05) and glucosamine 0.7; patient’s global assessment of efficacy as the sum of improvement good + ideal: 80.8% for Colatech® and 46.6% for glucosamine (p < 0.05). EHC (Colatech®) showed superior improvement over GS in the SF-36 Questionnaire in the Physical Health Index (42.0 for Colatech and 40.0 for glucosamine). The incidence of adverse events was similar in both groups. Both EHC and GS were well tolerated.

Keywords

Visual Analogue Scale Rescue Medication WOMAC Score Glucosamine Sulphate Secondary Efficacy Endpoint 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Adam M (1991) Therapie der osteoarthrosis. Welche Wirkung haben gelatinepräparate? Therapiewoche 41:2458–2461Google Scholar
  2. 2.
    Arquer A, Pujol P (1996) Physical exercise in the elderly people. Selección 5(3):121–128Google Scholar
  3. 3.
    Bellamy N, Carette S, Ford PM et al (1992) Osteoarthritis antirehumatic drug trials. II.Tables for calculating sample size for clinical trials. J Rheumatol 19:444–450PubMedGoogle Scholar
  4. 4.
    Bellamy N, Carette S, Ford PM et al (1992) Osteoarthritis antirehumatic drug trials. III. Setting the delta for clinical trials-results of a consensus development (Delphi) exercise. J Rheumatol 19:451–457PubMedGoogle Scholar
  5. 5.
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J Orthop Rheum 1:95–108Google Scholar
  6. 6.
    Hughes R, Carr A (2002) A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 41:279–284PubMedCrossRefGoogle Scholar
  7. 7.
    Jerosch J, Verdonk R, Trč T, Price A, Bailleul F, van Dijk NC (2008) Efficacy and safety of a single dose of Hylan G-20 vs. Placebo in patients with knee osteoarthritis pain. Knee Surgery Sport Traumatology Arthroscopy 16(Suppl 1):27–28Google Scholar
  8. 8.
    McAlindon T (2001) Glusoamine for osteoarthritis: dawn of a new era? Lancet 357:247–248PubMedCrossRefGoogle Scholar
  9. 9.
    Newman NM, Ling RS (1985) Acetabular bone destruction related to non-steroidal anti-inflammatory drugs. Lancet 2:11–14PubMedCrossRefGoogle Scholar
  10. 10.
    Noack W, Fischer M, Forster KK et al (1994) Glucosamine sulfate in osteoarthritis of the knee. Osteoarthr Cartil 2(1):51–59PubMedCrossRefGoogle Scholar
  11. 11.
    Oesser S, Adam M, Babel W, Seifert J (1999) Oral administration of 14C labelled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). J Nutr 129:1891–1895PubMedGoogle Scholar
  12. 12.
    Pavelka K, Trč T, Karpaš K et al (2007) The efficacy and safety of diacerein bn the treatment of painful osteoarthritis of the knee. Arthritis Rheum 56:4055–4064PubMedCrossRefGoogle Scholar
  13. 13.
    Pavelka K, Trč T, Karpaš K, Moster R, Audy P (2002) Treatment of knee osteoarthritis by intraarticular application of Hyalgan: clinical praxis experiences in Czech Republic. Acta Chir Orthop Traum Čech 69:302–304PubMedGoogle Scholar
  14. 14.
    Reginster JY, Gillot V, Bruyere O, Henrotin Y (2000) Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Curr Rheumatol Rep 2:472–477PubMedCrossRefGoogle Scholar
  15. 15.
    Reginster JY, Deroisy R, Rovatti LC et al (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo controlled clinical trial. Lancet 357:251–256PubMedCrossRefGoogle Scholar
  16. 16.
    Ribas J, Molinero O (1998) Effects of gelatine hydrolysatesin the prevention of sportsmen and women injuries. Arch Med Deport XV 66:277–282Google Scholar
  17. 17.
    Rindone J, Hiller D, Collacot E et al (2000) Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 172:91–94PubMedCrossRefGoogle Scholar
  18. 18.
    van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA (1989) Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 48:271–280PubMedCrossRefGoogle Scholar
  19. 19.
    Trč T, Handl M (1997) Hyaluronic acid experiences in treatment of arthritis. Acta Chir Orthop Traum Čech 64:95–98PubMedGoogle Scholar
  20. 20.
    Trentham D, Dynesius-Trentham R, Orav E et al (1993) Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727–1730PubMedCrossRefGoogle Scholar
  21. 21.
    Zeidler H (1991) Epidemiology and NSAID induced gastropathy. J Rheumatol 28(Suppl):2–5Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Orthopaedic Clinic, 2nd Medical SchoolCharles UniversityPragueCzech Republic
  2. 2.Rheumatology Department, Faculty Hospital BrnoBrnoCzech Republic

Personalised recommendations